Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | |
|---|---|---|---|---|---|
| 1 | 39 | 5 | 40 | ||
| 2 | 32 | metastatic | 3 | . | 3 |
| 3 | 3 | no previous therapy for | 2 | patients with clinical evidence of pancreatic insufficiency must be taking pancreatic enzyme replacement | 2 |
| 4 | 36 | resectable | 2 | or prior treatment with radiation for other diagnoses to expected pancreatic cancer treatment fields . | 2 |
| 5 | 49 | version v . 4 . 0 | 2 | patients must have failed a minimum of one previous line of therapy for advanced disease | 1 |
| 6 | 56 | prior treatment with chemotherapy or radiation for | 2 | is not allowed | 1 |
| 7 | 66 | prior therapy before day 1 of cycle 1 for the treatment of stage iv | 2 | or abdominal radiation therapy | 1 |
| 8 | 1 | cohort b group 2 | 1 | or any abdominal radiation therapy | 1 |
| 9 | 2 | previous systemic chemotherapy or radiation for | 1 | who have not previously received pembrolizumab . | 1 |
| 10 | 4 | previous treatment for | 1 | patients | 1 |
| 11 | 5 | a history of previous chemotherapy for | 1 | the last dose of chemotherapy must have been > = 4 months prior to study entry patients with prior radiotherapy are acceptable it must be at least 4 months since administration of radiation therapy and all signs of toxicity must have abated | 1 |
| 12 | 6 | patients must have no history of previous chemotherapy for | 1 | r n stage i iii cytologically or histologically proven pancreatic adenocarcinoma r n cancer confirmed to be surgically resectable with surgery evaluation with planned resection r n patients may have prior neoadjuvant chemotherapy | 1 |
| 13 | 8 | subjects with msi h | 1 | microcystic disease may be eligible | 1 |
| 14 | 9 | advanced | 1 | are eligible patients who received chemotherapy > = 5 years ago for malignancies other than pancreatic cancer are also eligible provided that chemotherapy was completed > = 5 years ago and that there is no evidence of the second malignancy at the time of study entry | 1 |
| 15 | 10 | phase ib no prior treatment with erlotinib is allowed for | 1 | who have measurable disease | 1 |
| 16 | 11 | patients may have had prior adjuvant treatment for | 1 | vaccine | 1 |
| 17 | 12 | for patients with | 1 | therapy symptomatic therapies are allowed | 1 |
| 18 | 13 | and / or investigational agents for | 1 | referred for image guided radiation therapy igrt | 1 |
| 19 | 14 | any prior treatment for | 1 | for the pancreatic cancer cohort | 1 |
| 20 | 15 | cystic | 1 | are eligible | 1 |
| 21 | 16 | first line treatment for metastatic | 1 | recurrence | 1 |
| 22 | 17 | any prior radiotherapy or chemotherapy for | 1 | based on imaging | 1 |
| 23 | 18 | patients who received recent chemotherapy for | 1 | cohort specific criteria r n patients must have unresectable or metastatic pancreatic cancer r n patients must have failed at least one prior line of therapy for metastatic or unresectable disease or have recurred within 6 months of completing adjuvant chemotherapy r n patients with liver metastases must have < 50 involvement of the liver | 1 |
| 24 | 19 | pre screening patients with advanced metastatic | 1 | = < 14 days prior to first dose of rucaparib | 1 |
| 25 | 20 | had prior systemic therapy for | 1 | after receiving 8 12 doses of folfirinox measurable disease is not required | 1 |
| 26 | 21 | for ly3300054 merestinib in | 1 | at fox chase cancer center fccc | 1 |
| 27 | 22 | have received any type of cancer immunotherapy including the same | 1 | 1 3 prior treatments | 1 |
| 28 | 23 | have received any anti | 1 | with chemotherapy in adjuvant setting except those where at least 12 months have elapsed since completion of the last dose and no persistent treatment related toxicities present | 1 |
| 29 | 24 | prior radiotherapy for | 1 | and beginning or continuing folfirinox chemotherapy | 1 |
| 30 | 25 | prior surgical resection of | 1 | within the past six months may be excluded at the discretion of the investigator | 1 |
| 31 | 26 | patients with pathologically confirmed | 1 | and have a first degree relationship with at least one of the relatives with pancreatic cancer r n if only 2 family members are affected then both must have had pancreatic cancer and a first degree relationship with individual screened r n if there are more than 2 affected individuals on the same side of the family at least one of the individuals must have a first degree relationship with the member being screened r n patients at least 40 years yrs old or 10 yrs younger than the youngest affected individual r n peutz jeghers syndrome pjs patients age > = 30 r n hereditary pancreatitis patients r n patients with familial atypical mmcLtiple mole melanoma syndrome fammm r n patients with brca2 mutation and at least one first or second degree relative with documented pancreatic cancer | 1 |
| 32 | 27 | locally advanced or metastatic | 1 | surgeon or a mmcLti disciplinary or gastrointestinal oncology tumor board | 1 |
| 33 | 28 | prior systemic therapy for | 1 | other than up to 4 cycles of mfolfirinox as noted above | 1 |
| 34 | 29 | or radiotherapy for resectable | 1 | and must conform to one or more of the following requirements r n have a strong family history of pancreatic cancer this is defined as pancreatic cancer occurring in one first degree relative and two other relatives | 1 |
| 35 | 30 | patients who received chemotherapy > = 5 years ago for malignancies other than | 1 | r n family history will be defined as pancreatic cancer occurring in one first degree relative and two other relatives or two first degree relatives | 1 |
| 36 | 31 | prior use of radiotherapy or investigational agents for | 1 | for whom the treatment plan | 1 |
| 37 | 33 | prior radiation therapy for | 1 | resection | 1 |
| 38 | 34 | radiographic evidence of | 1 | patient inclusion criteria | 1 |
| 39 | 35 | prior abdominal radiation therapy or prior chemotherapy for | 1 | patient exclusion criteria | 1 |
| 40 | 38 | prior surgical or medical treatment for | 1 | NA | |
| 41 | 40 | received any systemic treatment for | 1 | NA | |
| 42 | 41 | no prior chemotherapy or radiation for | 1 | NA | |
| 43 | 42 | no definitive resection of | 1 | NA | |
| 44 | 43 | have stable metastatic | 1 | NA | |
| 45 | 44 | patients who have had any prior therapy for | 1 | NA | |
| 46 | 47 | subjects with one or more prior treatments for their | 1 | NA | |
| 47 | 48 | prior chemotherapy or radiation for | 1 | NA | |
| 48 | 50 | subjects who have had radiotherapy for | 1 | NA | |
| 49 | 51 | patients must have had no prior chemotherapy or radiation therapy for | 1 | NA | |
| 50 | 53 | immunotherapy or any clinical trials or radiotherapy for | 1 | NA | |
| 51 | 54 | maldigestion / malabsorption syndrome pre dating the diagnosis of | 1 | NA | |
| 52 | 55 | no prior treatment for | 1 | NA | |
| 53 | 57 | prior treatment with any chemotherapy for metastatic disease from | 1 | NA | |
| 54 | 60 | part b only prior therapy including investigational agents for | 1 | NA | |
| 55 | 62 | any prior treatment chemotherapy radiation for | 1 | NA | |
| 56 | 63 | patient must not have received prior chemotherapy or radiation for | 1 | NA | |
| 57 | 64 | prior chemotherapy immunotherapy or radiation for | 1 | NA | |
| 58 | 65 | surgery or investigational therapy for adjuvant or metastatic | 1 | NA | |
| 59 | 68 | are undergoing treatment for | 1 | NA | |
| 60 | 69 | mesothelioma | 1 | NA | |
| 61 | 70 | prior treatment of | 1 | NA | |
| 62 | 71 | observational arm only patients with a pathological or clinical diagnosis of | 1 | NA | |
| 63 | 72 | minocycline trial only patients who have had prior treatment for | 1 | NA | |
| 64 | 73 | one of the following high risk groups r n patients will be eligible if they have 2 or more relatives with | 1 | NA | |
| 65 | 74 | determined unresectable by a | 1 | NA | |
| 66 | 75 | patients who have received chemotherapy for | 1 | NA | |
| 67 | 76 | and 3 group 1 participants identified as being high risk for familial or hereditary | 1 | NA | |
| 68 | 77 | or family history of | 1 | NA | |
| 69 | 78 | patients with histologic or cytologic proof of | 1 | NA | |
| 70 | 79 | any prior systemic or investigational therapy for | 1 | NA | |
| 71 | 80 | undergoing | 1 | NA |